Progression to IBD-CRC is driven by a series of rate-limiting evolutionary events (such as TP53 mutation and critical copy number changes as described earlier in the review), while ongoing accumulation of heterogeneous genomic alterations occurs via genetic drift in crypts throughout patient lifetime. This evidence concerns the gene TP53 and colorectal carcinoma.